BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1162 related articles for article (PubMed ID: 23868944)

  • 1. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
    Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
    Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
    Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
    Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
    Lønborg J; Vejlstrup N; Kelbæk H; Bøtker HE; Kim WY; Mathiasen AB; Jørgensen E; Helqvist S; Saunamäki K; Clemmensen P; Holmvang L; Thuesen L; Krusell LR; Jensen JS; Køber L; Treiman M; Holst JJ; Engstrøm T
    Eur Heart J; 2012 Jun; 33(12):1491-9. PubMed ID: 21920963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
    Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of cardiac troponin-I compared to creatine kinase-myocardial band for the assessment of infarct size as measured by cardiac magnetic resonance.
    Di Chiara A; Dall'Armellina E; Badano LP; Meduri S; Pezzutto N; Fioretti PM
    J Cardiovasc Med (Hagerstown); 2010 Aug; 11(8):587-92. PubMed ID: 20588136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective Effects of Intracoronary Morphine in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial.
    Gwag HB; Kim EK; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Lee SH; Chang SA; Park SJ; Lee SC; Park SW; Jang WJ; Lee M; Chun WJ; Oh JH; Park YH; Choe YH; Gwon HC; Hahn JY
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28373244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between discharge heart rate and left ventricular adverse remodelling in ST segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
    Joyce E; Hoogslag GE; Leong DP; Fox K; Schalij MJ; Marsan NA; Bax JJ; Delgado V
    Heart; 2013 Apr; 99(8):556-61. PubMed ID: 23468514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.
    De Luca G; Gibson M; Cutlip D; Huber K; Dudek D; Bellandi F; Noc M; Maioli M; Zorman S; Zeymer U; Secco GG; Mesquita Gabriel H; Emre A; Arntz HR; Rakowski T; Gyongyosi M; Hof AW;
    Arch Cardiovasc Dis; 2013 Mar; 106(3):155-61. PubMed ID: 23582677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
    Lønborg J; Kelbæk H; Vejlstrup N; Bøtker HE; Kim WY; Holmvang L; Jørgensen E; Helqvist S; Saunamäki K; Terkelsen CJ; Schoos MM; Køber L; Clemmensen P; Treiman M; Engstrøm T
    Circ Cardiovasc Interv; 2012 Apr; 5(2):288-95. PubMed ID: 22496084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
    Post S; Post MC; van den Branden BJ; Eefting FD; Goumans MJ; Stella PR; van Es HW; Wildbergh TX; Rensing BJ; Doevendans PA
    Catheter Cardiovasc Interv; 2012 Nov; 80(5):756-65. PubMed ID: 22419603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.
    Roubille F; Micheau A; Combes S; Thibaut S; Souteyrand G; Cayla G; Bonello L; Lesavre N; Sportouch-Dukhan C; Klein F; Berboucha S; Cade S; Cung TT; Raczka F; Macia JC; Gervasoni R; Cransac F; Leclercq F; Barrère-Lemaire S; Paganelli F; Mottref P; Vernhet Kovacsik H; Ovize M; Piot C
    Arch Cardiovasc Dis; 2013 Mar; 106(3):135-45. PubMed ID: 23582675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Chia S; Senatore F; Raffel OC; Lee H; Wackers FJ; Jang IK
    JACC Cardiovasc Interv; 2008 Aug; 1(4):415-23. PubMed ID: 19463339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprocedural hyperglycemia in ST elevation myocardial infarction submitted to percutaneous coronary intervention: a prognostic indicator and a marker of metabolic derangement.
    Lazzeri C; Chiostri M; Sori A; Valente S; Gensini GF
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):7-13. PubMed ID: 19829142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report.
    Farkouh ME; Reiffel J; Dressler O; Nikolsky E; Parise H; Cristea E; Baran DA; Dizon J; Merab JP; Lansky AJ; Mehran R; Stone GW
    Circ Cardiovasc Interv; 2013 Jun; 6(3):216-23. PubMed ID: 23652600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of necrosis markers and cardiovascular magnetic resonance-derived microvascular perfusion in reperfused ST-elevation myocardial infarction.
    Husser O; Bodi V; Sanchis J; Nunez J; Mainar L; Rumiz E; Lopez-Lereu MP; Monmeneu JV; Forteza MJ; Oltra R; Riegger GA; Chorro FJ; Llacer A
    Thromb Res; 2009 Nov; 124(5):592-600. PubMed ID: 19540571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome c release in acute myocardial infarction predicts poor prognosis and myocardial reperfusion on contrast-enhanced magnetic resonance imaging.
    Liu ZB; Fu XH; Wei G; Gao JL
    Coron Artery Dis; 2014 Jan; 25(1):66-72. PubMed ID: 24077325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: a substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial.
    Hallén J; Petzelbauer P; Schwitter J; Geudelin B; Buser P; Atar D
    EuroIntervention; 2010 Apr; 5(8):946-52. PubMed ID: 20542780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.